Healthcare Enterprise Group rebuilds platform for innovative product R&D (research & development)
This article was originally published in Clinica
When UK AIM-listed Healthcare Enterprise Group's medical technologies business model ran into trouble in late 2005, two board members stepped up to lead a recovery. Nine months and some radical decision-making later, the original business plan has been slotted back in place. HCEG non-executive chairman Mark Tompkins told Ashley Yeo what happened, why and what comes next
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.